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INTRODUCTION
The Diagnostic and Statistical Manual of Mental Disorders 
defines insomnia as dissatisfaction with sleep quantity or 
quality accompanied by difficulty in initiating sleep, difficulty 
in maintaining sleep, or early-morning awakening with an 
inability to return to sleep despite adequate opportunity for 
sleep. If these sleep disturbances cause clinically significant 
distress in important areas of functioning and occur at least 
three nights per week for at least three months, a diagnosis of 
insomnia is warranted.1 Insomnia is receiving increasing at-
tention because of its impact on quality of life, relationship to 
other medical conditions,2,3 and psychiatric disorders,4,5 and 
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association with increased mortality rates among patients with 
congestive heart failure, coronary diseases, and metabolic 
diseases.6 Insomnia is quite common, affecting 8–17% of the 
general population,7,8 and its prevalence increases with age, 
lower socioeconomic status, and concurrent medical and psy-
chiatric comorbidity.9 However, only 5% of individuals with 
chronic insomnia seek help for their sleep problems from a 
health care provider.10 
Guidelines recommend cognitive behavioral therapy for in-
somnia (CBT-i) as a first-line treatment for insomnia.11,12 De-
spite these guidelines, doctors still routinely prescribe hyp-
notics for insomnia.13 Although hypnotics effectively reduce 
the symptoms of insomnia, they cause many side effects in-
cluding increased risk of falls resulting in fracture, cognitive 
impairment, impaired motor coordination, sedation, confu-
sion, motor vehicle accidents, and dependence.14,15 In con-
trast, CBT-i treats insomnia by modifying thought patterns 
and behaviors that reinforce poor sleep, with minimal side ef-
fects and no potential for dependency. Previous studies show 
that CBT-i improves sleep efficiency, increases total sleep time, 
and reduces wake time after sleep onset in patients with in-
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somnia.16-18 CBT-i exerts similar short-term therapeutic effects, 
but better long-term therapeutic effects on insomnia symp-
toms than hypnotics.19 However, there are some barriers to 
administering CBT-i to insomnia patients. Changing thought 
patterns and behaviors takes more effort than taking medica-
tion, and patience is required to see treatment effects. Further-
more, patients may not want to visit the clinic every week to 
receive CBT-i. For these reasons, patients and clinicians are 
reluctant to use CBT-i despite knowledge of its benefits, and 
insomnia patients often receive pharmacotherapy in addition 
to CBT-i. 
This study determined whether insomnia patients who re-
ceived CBT-i had 1) a reduced need for sleep medications 
and 2) better treatment outcomes during long-term follow-
up than control patients who received pharmacotherapy only. 
Using a retrospective study design, we reviewed outpatient 
clinic data from a psychiatry department in a general hospi-
tal setting and compared prescribed medication dosages and 
treatment outcomes between CBT-i and control groups. 
METHODs 
Participants 
We reviewed electronic medical records of patients diag-
nosed with and initiating treatment for insomnia (G47.0) or 
primary insomnia (F51.0) in the Severance Hospital outpatient 
clinic from January 2009 to December 2014. We found 41 pa-
tients who completed five sessions of CBT-i as confirmed by 
doctors’ orders and payment statements. For comparison, we 
selected 100 outpatients with the same diagnoses who did 
not receive CBT-i during the same period matched for age, 
sex, and medical comorbidity. We excluded those cases diag-
nosed with major psychiatric disorders including schizophre-
nia spectrum and other psychotic disorders, bipolar I disor-
der, major depressive disorder, persistent depressive disorder, 
substance use disorder, or sleep apnea as a principal diagno-
sis in order to focus on insomnia treatment. Because of the 
small sample size, we did not exclude any psychiatric diagno-
sis for the CBT-i group. As a result, we included 141 patients. 
We followed up using their medical records through Decem-
ber 2015 for the evaluation of successful treatment. The In-
stitutional Review Board of Severance Hospital approved this 
study (4-2015-1027).
Procedures 
Our CBT-i program was based on Edinger’s CBT-i proto-
col.20 The program was implemented as five weekly 90-min-
ute therapy sessions discussing an introduction to the method, 
stimulus control, sleep restriction, sleep hygiene, and cogni-
tive therapy and trouble-shooting. We provided the treatment 
program to groups of 2–4 persons served by two mental health 
professionals (one psychiatrist and one nurse). As the CBT-i 
program is not an exclusive treatment arm in our hospital, pa-
tients could also receive pharmacotherapy. In this data, CBT-
i was performed between January 2009 and December 2014.
Measurement
We reviewed the electronic medical records to obtain infor-
mation about patients’ sex, age, comorbid medical and psychi-
atric conditions, prescribed medications for sleep, total num-
ber of clinic visits, first and last visit dates, total duration of 
follow-up, clinical global impression (CGI), and status of case 
closure at the last visit as indicated by doctors’ comments. 
Because most patients undergoing CBT-i also were prescribed 
medications for sleep, we evaluated the additive effect of CBT-
i to their treatment regimen. As the benefits of CBT-i are evi-
dent after 12 months of treatment,19,21 we investigated 1) 
changes in the need for sleep medications between the first 
and last visits and 2) treatment outcome at the last visit. 
To evaluate changes in the need for sleep medications, we 
reviewed data on all prescribed medications for sleep at the 
first and last clinic visits. We sorted prescribed medications 
into three categories: hypnotics, antidepressants, and other 
medications. In the case of hypnotics, we separated them 
into two categories based on elimination half-lives: short-
acting (<24 hours) and long-acting (≥24 hours) hypnotics.22 
We investigated the prescription rate and the dosage of sleep 
medication at the first and the last visit. We also examined the 
prescription rate and dosage of mirtazapine and trazodone 
specifically because of their frequent off-label use for insom-
nia.23 To evaluate the prescribed dosages, we converted the 
antidepressant dosage to dose equivalent of fluoxetine24,25 
and the hypnotic dosage to dose equivalent of lorazepam.26
To evaluate treatment outcome, we assessed doctors’ com-
ments at the last visit and categorized CGI as follows: improve-
ment, no change, or decline. We also assessed the status of 
case closures, which were defined as meeting two conditions: 
1) doctor’s comment that specified case closure on the last 
outpatient clinic visit and 2) absence of next visit appointment. 
If there was no comment about case closure, we defined it as 
“lost to follow-up.” If a next visit appointment was present af-
ter 12/31/2015, the case was defined as “treatment mainte-
nance.”
statistical analysis 
We performed Chi-square statistical analysis to compare 
prescription rates from the first to the last visits and between 
the CBT-i and the control group. We also conducted repeated 
measures analysis of variance (ANOVA) to examine the change 
in prescribed dosage of hypnotics and antidepressants from 
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the first to last visits between the two groups. We did not an-
alyze the converted dosage of other medications because of 
their relatively low occurrence (<5%). We excluded “as need-
ed” prescriptions, because it was difficult to know exact use 
of these medications. Comparison of CGI and status of case 
closure between the two groups were performed using chi-
squared analysis. Independent sample t-tests and chi-squared 
tests were used to compare continuous and categorical vari-
ables between CBT-i and control patients, respectively. Data 
analyses were conducted using SPSS for Windows version 20 
(IBM Corp., Armonk, NY, USA), and statistical significance 
was set at p<0.05.
REsUlTs 
Demographic and clinical characteristics 
Patients ranged in age from 20 to 84 years. Within the CBT-
i group, psychiatric comorbidities were generalized anxiety 
disorder (n=1), major depressive disorder (n=2), bipolar II 
disorder (n=1), acute stress disorder (n=1), and panic disorder 
(n=2). Within the control group, psychiatric comorbidities 
were: generalized anxiety disorder (n=1), panic disorder (n=7), 
somatic symptom disorder (n=3), and social phobia (n=1). 
We found no significant difference in the frequency of psy-
chiatric comorbidities between groups (Table 1). Among the 
control patients, five started their psychiatric treatment dur-
ing admission. None required re-hospitalization for psychiat-
ric comorbidity during the observation period. Their diagnoses 
were as follows: two adjustment disorders, two depressive 
disorders, and one anxiety disorder. None were admitted for 
psychiatric comorbidity in the CBT-i group.
As our institution is a general hospital, approximately one-
third of CBT-i and control patients had medical comorbidi-
ties, including hypertension, diabetes mellitus, thyroid dis-
ease, cardiovascular disease, migraine, herniated cervical discs, 
and cancer. No patients had uncontrolled medical illness, 
and there was no significant difference in the frequency of 
medical comorbidities between groups (Table 1). There were 
four patients with cancer in the CBT-i group (breast cancer, 
n=2; thyroid cancer, n=1; acute myeloblastic leukemia, n=1) 
and ten patients with cancer in the control group (advanced 
gastric cancer, n=2; breast cancer, n=6; thyroid cancer, n=1; sig-
moid colon cancer, n=1). All patients with cancer were in a sta-
ble disease state and were not admitted during the study pe-
riod, except for scheduled chemotherapy (CBT-i group, n=1; 
control group, n=1). 
Need for sleep medication
We compared the differences in the prescription rate be-
tween the two groups at their first and the last visit (Table 2). 
Table 1. Demographic and clinical characteristics of patients
CBT-i (N=41) Control (N=100) p
Mean age, years (SD) 51.80 (14.62) 52.12 (14.04) 0.90
Sex, male/female 10/31 26/74 0.84
Patients with psychiatric comorbidities, N (%) 7 (17) 13 (13) 0.33
Patients with medical comorbidities, N (%) 13* (31) 34† (34) 0.80
Patients with cancer, N (%) 4‡ (10) 10§ (10) 0.97
Mean duration of total follow-up, days (SD) 541.85 (694.95) 610.09 (643.33) 0.58
*hypertension (N=3), diabetes mellitus (N=2), chronic heart failure (N=1), destroyed lung due to old pulmonary tuberculosis (N=1), cancer 
(N=4), †hypertension (N=8), diabetes mellitus (N=3), coronary artery disease (N=3), end stage renal disease (N=2), migraine (N=2), asthma 
(N=1), herniated cervical disc (N=1), osteoporosis (N=1), hyperthyroidism (N=1), aneurysm (N=1), cancer (N=10), ‡breast cancer (N=2), 
thyroid cancer (N=1), acute myeloblastic leukemia (N=1), §breast cancer (N=6), advanced gastric cancer (N=2), thyroid cancer (N=1), sig-
moid colon cancer (N=1). CBT-i: cognitive behavioral therapy of insomnia, SD: standard deviation 
Table 2. Prescribed medications at the first and last visit
First visit
p
Last visit
p
CBT-i (N=41) Control (N=100) CBT-i (N=41) Control (N=100)
Any pharmacotherapy, N (%) 35 (85) 94 (94) 0.11 22 (53) 91 (91) <0.001
Hypnotics, N (%) 33 (81) 92 (92) 0.08 23 (56) 90 (90) <0.001
Antidepressants, N (%) 20 (49) 65 (65) 0.07 12 (30) 54 (54) 0.01
Others, N (%) 2* (5) 3† (3) 0.63 0 (0) 5‡ (5) 0.32
Short-acting hypnotics, N (%) 29 (71) 83 (83) 0.10 20 (49) 74 (74) 0.004
Long-acting hypnotics, N (%) 8 (20) 29 (29) 0.25 6 (15) 39 (39) 0.005
*quetiapine (N=2), †buspirone (N=3), ‡quetiapine (N=2) and buspirone (N=3). CBT-i: cognitive behavioral therapy of insomnia
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At the first visit, no difference was found. However, at the last 
visit, the prescription rates of hypnotics and antidepressant 
in the CBT-i group were significantly lower than in the con-
trols. We also examined the prescription rate and dosage of 
mirtazapine and trazodone, and found no differences at either 
the first or the last visit. 
We examined changes in the dosages of prescribed sleep 
medications between the first and last visits using repeated 
measures of ANOVA. We found a significant change in group 
by time interaction on hypnotic dosage (Table 3). The dosage 
of hypnotics decreased over time in the CBT-i group; howev-
er, it remained the same in the control group (Figure 1). We 
found no significant change in group by time interaction on the 
dosage of antidepressants over time.
Treatment outcome
We performed χ2 tests for CGI and status of case closure at 
the last visit for comparison of treatment outcomes. Achieve-
ment of case closure was better in the CBT-i group at the 
trend level (Table 4). However, the number of improved cases 
evaluated by CGI at the last visit was not significantly differ-
ent between the two groups (80.6% in the CBT-i group vs. 81% 
in the control group, p=0.17). 
DIsCUssION
We found CBT-i reduced the need for hypnotics among pa-
tients with insomnia. Previous studies show that CBT-i im-
proves sleep efficiency, increases total sleep time, and reduces 
wake time after sleep onset.18 Thus, in contrast to most previ-
ous studies that focused on sleep characteristics, our study is 
unique because it examined the effect of CBT-i on the prescrip-
tion of sleep medications routinely combined with CBT-i.27,28 
Hypnotic use increases the risk of abuse, decreases cogni-
tive function, and increases traffic accidents and falls in a 
dose-dependent manner.14,29 Thus, our finding that CBT-i de-
creased the prescription rate and dosage of hypnotics can help 
avoid those risks. Our result is consistent with that of a previ-
ous study showing a decrease in sleep medication use among 
patients receiving internet-based CBT-i.30 Few studies have 
examined the role of CBT-i in reducing the use of hypnotics. 
Belleville et al.31 reported outstanding benefits from CBT-i 
Table 3. Comparison of dose changes in prescribed medications for sleep between the CBT-i and control groups
Outpatient visit CBT-i Control
Group Group×time Time
F p F p F p
Hypnotics, mean (SD) 7.23 0.01 14.27 <0.001 1.74 0.19
First visit 1.30 (1.03) 1.24 (0.90)
Last visit 0.69 (0.85) 1.53 (1.14)
Antidepressants, mean (SD) 0.20 0.65 1.93 0.17 0.53 0.47
First visit 3.86 (6.04) 3.38 (4.20)
Last visit 3.44 (7.68) 4.70 (6.34)
The antidepressant dosage was converted to dose equivalent of fluoxetine, and the hypnotic dosage was converted to dose equivalent of loraz-
epam. CBT-i: cognitive behavioral therapy of insomnia, SD: standard deviation 
Figure 1. Prescription of hypnotics for insomnia. CBT: cognitive 
behavioral therapy. 
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Table 4. Status of treatment at the last visit
CBT-i
(N=41)
Control
(N=100) p
Case closure, N (%) 6 (15) 4 (4)
0.07Lost to follow-up, N (%) 27 (66) 78 (78)
Treatment maintenance, N (%) 8 (20) 18 (18)
CBT-i: cognitive behavioral therapy of insomnia
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on tapering hypnotics in self-help insomniacs. On the other 
hand, Taylor et al.32 showed no change in hypnotic use after 
CBT-i among hypnotic dependent patients. We assume that 
the comorbid condition of hypnotic dependence made CBT-
i less effective. Our study is not comparable with Taylor’s study 
because we excluded patients with substance abuse disorders. 
In another study showing no superior effect of CBT-i, total du-
ration of follow-up was a relatively short 3 months.33 There 
are only five cases with reduced prescription dosage by more 
than half in their first month after CBT-i. However, during the 
follow-up period after CBT-i, which was 513 days in average, 
twelve out of 41 patients quit hypnotics. This is a consistent 
finding that the effect of CBT-i is incremental rather than im-
mediate.16,17
Previous studies report that CBT-i is helpful for insomnia 
patients with major depressive disorder and is an effective aug-
mentation therapy for depression itself.34 However, we found 
no significant change in antidepressant use after CBT-i, per-
haps because of the low dosage of prescribed antidepressants 
in our study. Specifically, the prescribed antidepressant dosage 
was similar between groups and equivalent to a fluoxetine 
dose of 3.5–5 mg, which is lower than the therapeutic dosage 
for depressive disorder. Indeed, antidepressant dosages for 
primary insomnia tends to be lower than those for major de-
pressive episodes.35 As only two patients in our study had co-
morbid major depressive disorder, we speculate that antide-
pressants were prescribed not for the depression per se, but 
rather for sleep disturbances. This may explain why we ob-
served no change in antidepressant dosage in either group.
Previous studies showed that medical comorbidities such 
as cardiovascular disease, diabetes, cancer, and some medica-
tions can influence the insomnia state.36-39 Approximately 30% 
of patients had medical comorbidities, which may be due to 
our hospital being a general hospital. We thought that these 
medical comorbid states may affect the results. However, we 
found medical comorbidity had no effect on the prescription 
rate and dosage of sleep medications in either group. Previous 
studies confirm the efficacy of CBT-i among insomnia patients 
with medical comorbidities.40,41 Even though some patients 
had cancer, there were no unplanned admissions. Therefore, 
we can speculate that CBT-i reduces hypnotic prescription in 
patients with medical comorbidities as well as in healthy in-
somniacs.
We speculate that the continued use of hypnotics after CBT-
i is associated with doctors’ or patients’ reluctance to stop medi-
cation because of the fear of insomnia recurrence. This fear 
may be due to the chronic nature of these sleep disturbances. 
In addition, the average follow-up duration of patients who 
received CBT-i was more than 500 days, which is also indica-
tive of the chronic nature of their insomnia. Chronic insomnia 
may be maintained by its self-perpetuating nature, involving 
selective attention and monitoring, distorted perceptions of 
daytime deficits, and counterproductive safety behaviors.42 A 
previous study showed that the prognosis of insomnia pa-
tients after CBT-i was better when use of hypnotics was stopped 
entirely, than when using these drugs as needed.17 Although 
additional research is needed, our results indicate that doctors 
should try to stop prescribing hypnotics after CBT-i.
Our study has some limitations, mostly related to its retro-
spective design. First, our study has a small sample size. Be-
cause we included only patients who completed five sessions 
of CBT-i as confirmed by doctors’ orders and payment state-
ments, only 41 patients were included in the final cohort. Sec-
ond, selection bias may have been present. In the clinic, doc-
tors might have recommended CBT-i to patients with milder 
symptoms, greater motivation, or greater financial or time re-
sources. However, there were no significant differences be-
tween groups in regard to clinical characteristics or medica-
tion dosages at the first visit, thus minimizing the possibility 
of selection bias. Last, we could not completely exclude cases 
with psychiatric or medical comorbidities because of our study 
being conducted in a general hospital setting. Although we 
found no effect of psychiatric or medical comorbidities on 
the results, there are still possibilities that either comorbidi-
ties or their treatments could affect the study results.
In summary, we show that CBT-i reduces the need for hyp-
notics in insomnia patients. This finding is important because 
CBT-i can reduce the risk of accidents and complications as-
sociated with hypnotic use. Our results indicate that CBT-i 
offers additional benefits beyond improving sleep character-
istics, and thus provides further reasons to recommend CBT-
i as a first-line treatment for insomnia.
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